Cancer is a general name for a large group of diseases that can affect any part of the body. Over the past decades, cancer research and treatment have achieved tremendous success, but cancer still remains a great challenge for humanity, and brings pains and difficulties to patients those living with it. Cancer cells have many significant biological characteristics, such as the ability to exhibit unlimited proliferative potential, maintain continuous stability of their own growth signals, evade apoptosis induced by stress signals (e.g. therapeutic drugs), stimulate vascular growth, provide nutrition to the tumor, evade immune system defense, induce local chronic inflammation, exert invasive and metastatic capabilities, exhibit abnormal metabolic activities, and significantly alter genome-wide stability through mutations and epigenetic mechanisms.
BOC Sciences has carefully designed an anti-cancer screening library containing more than 6,000 novel drug-like screening compounds with potential anti-tumor activity against various cancer types such as prostate and breast cancers, leukemia, lymphoma, and carcinoma.
Figure 1. Small Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics. (Chen, B. J.; et al. 2014)
Anti-Cancer Compound Library Characteristics
We cooperate with leading experts in the field of focused/targeted library construction to design and supply top-level libraries, aiming to meet different requirement of each client. BOC Sciences anti-cancer compound library provides compounds containing potential inhibitory activity against the following cancer cell lines for different cell-based phenotypic screening projects:
Table1. Compounds in BOC Sciences anti-cancer compound library contains inhibitory activity against the following cancer cell line
| 3LL | HONE1 | NCI/ADR-RES |
| A253 | HT-29 | NCI-H157 |
| A-375 | Human T-cell line | NCI-H2009 |
| A549 | Jurkat | NCI-H460 |
| AGS | K562 | NUGC-3 |
| B16-F10 | KB | P388 |
| BC1 | KU812 | Panel leukemia (Carcinoma cell lines) |
| Bel-7402 | KYSE-150 | Panel NCI-60 (60 carcinoma cell lines) |
| BGC-823 | KYSE-70 | PC-3 |
| CCRF-CEM | Leukemia 60 cell line | SF-268 |
| CHRC5 | Lewis lung carcinoma cell line | SF-295 |
| DU-145 | LNCaP | SH-SY5Y |
| Fibrosarcoma cell line | LoVo | SK-MEL-5 |
| HBL-100 | LOX IMVI | SK-OV-3 |
| HCC 2998 | Lung cancer cell line | T-24 |
| HCT-116 | LXF-289 | T98G |
| HeLa | M14 | THP-1 |
| Hepatoblastoma cell line | MCF7 | TK-10 |
| HepG2 | MDA-MB-231 | U-937 |
| HL-60 | Melanoma tumor cell line | UO-31 |
| HNO 97 | MOLT-4 |
BOC Sciences anti-cancer compound library is able to be used to select approximately 4,800 potential anti-cancer compounds for the following targets:
- Anoctamin-1
- Lysine-specific demethylase 5B
- ATP-binding cassette sub-family G member 2
- MAP kinase p38 alpha
- Beta-hexosaminidase subunit beta
- Mitogen-activated protein kinase kinase kinase 8
- Breast cancer type 1 susceptibility protein
- Mixed lineage kinase 7
- Bromodomain testis-specific protein
- Nuclear receptor coactivator 3
- Cyclin-dependent kinase 2-associated protein 1
- PDZ-binding kinase
- L-type amino acid transporter 3
- Serine/threonine-protein kinase WNK2
Anti-Cancer Compound Library Design
- No PAINS or toxic substances/unwanted functions: filtered by strict ‘Ro5-like’ physicochemical and most stringent in-house structural filters
- Our anti-cancer compound library is designed to be a useful tool for high-throughput screening (HTS) in anti-cancer drug discovery studies
- We employ a similarity search method against publicly available databases of reported antitumor active molecules
- The compounds will be first screened compounds from the HTS compound collection by similarity search
- All of these compounds possess assigned activity values lower than 10 mM and with 80% similarity cut-off (Tanimoto)
- Compound cherry-picking service is provided
What We Deliver
- Delivered within 2 weeks in any customer-preferred format
- Powders, dry films or DMSO solutions formatted in vials, 96 or 384-well plates
- All compounds have a minimum purity of 90% assessed by 1H NMR
- Analytical data is provided
BOC Sciences provides professional, rapid and high-quality services of Anti-Cancer Compound Library design at competitive prices for global customers. Personalized and customized services of Anti-Cancer Compound Library design can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!
Reference
- Chen, B. J.; et al. Small Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics. International Journal of Biological Sciences. 2014. 10(10): 1084-96.
